Integrin

Integrin製品

• All (35)
• Integrin阻害剤 (12)
• Integrin抗体(12)
• Integrin拮抗剤(7)
• Integrin作動薬(2)
• 新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S7077	Cilengitide trifluoroacetate	Cilengitide (EMD 121974, NSC 707544) is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.	Adv Sci (Weinh), 2023, e2307206. Heliyon, 2023, 9(9):e20185 Heliyon, 2023, 9(9):e20185
S6387	Cilengitide	Cilengitide (EMD 121974, EMD-12192, EMD-85189, NSC-​707544) is a potent and selective inhibitor of the integrins ανβ3 and ανβ5 with IC50 of 4 and 79 nM, respectively.	NPJ Regen Med, 2024, 9(1):4 World J Gastroenterol, 2024, 30(7):728-741 Cancer Cell, 2023, 41(8):1480-1497.e9
S7540	SB273005	SB273005 is a potent integrin inhibitor with Ki of 1.2 nM and 0.3 nM for αvβ3 receptor and αvβ5 receptor, respectively.	Cancer Lett, 2024, 582:216597 Nat Commun, 2023, 14(1):3251 Neuron, 2023, S0896-6273(23)00623-2
S8008	RGD (Arg-Gly-Asp) Peptides	RGD (Arg-Gly-Asp) Peptides is a cell adhesion motif which can mimic cell adhesion proteins and bind to integrins.	J Sport Health Sci, 2024, S2095-2546(24)00124-8 iScience, 2024, 27(3):109119 Cell Stem Cell, 2023, 30(6):867-884.e11
S8454	ATN-161	ATN-161 is a novel small peptide antagonist of integrin α5β1. It binds to several integrins, including α5β1 and αvβ3, that play a role in angiogenesis and tumor progression.	Nat Commun, 2024, 15(1):5986 Int Immunopharmacol, 2024, 141:112947 Bioact Mater, 2023, 22:75-90
S7844	Cyclo(RGDyK)	Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with IC50 of 20 nM.	J Clin Invest, 2024, e175147 Cell Commun Signal, 2023, 10.1186/s12964-022-01027-7 iScience, 2023, 26(6):106839
S7834	Cyclo(-RGDfK) TFA	Cyclo(-RGDfK) TFA is a potent and selective αvβ3 integrin inhibitor.	Sci Adv, 2024, 10(43):eadp4726 bioRxiv, 2024, 2024.09.17.613509 Oxidative Medicine and Cellular Longevity, 2021, 10.1155/2021/9739977
S8306	Leukadherin-1	Leukadherin-1 (LA1) is a small molecule agonist that enhances CD11b/CD18-dependent cell adhesion to its ligand ICAM-1(an agonist for the complement receptor 3 (CD11b/CD18)).	International Immunopharmacology, 2023, Volume 118 Int Immunopharmacol, 2023, 118:110024 Front Immunol, 2022, 13:919444
S2885	A-205804	A-205804 is a potent and selective inhibitor of E-selectin and ICAM-1 expression with IC50 of 20 nM and 25 nM respectively.	Cell Biol Toxicol, 2024, 40(1):90 Stem Cell Res Ther, 2022, 13(1):218 Am J Rhinol Allergy, 2022, 19458924221086061
S3714	Lifitegrast	Lifitegrast (SAR1118,SHP-606) is a novel small molecule integrin antagonist that inhibits a specific T cell-mediated inflammatory pathway involved in the pathogenesis of DED.	Med Oncol, 2024, 41(8):188 World J Gastroenterol, 2023, 29(20):3103-3118 Med Chem Res, 2022, 31(4):555-579
S3085	Tirofiban	Tirofiban (MK-383) is a selective platelet GPIIb/IIIa antagonist which inhibits platelet aggregation with IC50 of 9 nM.	Food Funct, 2020, 11(1):139-152
S8594	Tirofiban Hydrochloride	Tirofiban Hydrochloride (MK-383) is the hydrochloride salt form of tirofiban, a selective platelet GPIIb/IIIa antagonist which inhibits platelet aggregation. It is more soluable than Tirofiban.	J Immunother Cancer, 2024, 12(11)e009805 Transl Oncol, 2024, 39:101813 Front Cell Infect Microbiol, 2021, 11:783085
S6840	OSU-T315	OSU-T315 (ILK-IN-2) is a potent Integrin-Linked Kinase (ILK) inhibitor with IC50 of 0.6 μM. OSU-T315 induces autophagy and apoptosis, both of which are integral to its antiproliferative activity. OSU-T315 exhibits anti-tumor activity.	Exp Eye Res, 2023, 234:109609
E0462	Pyrintegrin	Pyrintegrin is an β1-integrin agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival, also enhances cell-extracellular matrix (ECM) adhesion-mediated integrin signaling.	Signal Transduct Target Ther, 2024, 9(1):109 Signal Transduct Target Ther, 2024, 9(1):109
A2420	Anti-Integrin b1 / ITGB1 / CD29	Anti-Integrin b1 / ITGB1 / CD29 is a humanized monoclonal antibody directed against the human integrin receptor beta-1 subunit (CD29), with potential antineoplastic activity. MW: 145.5 kD.
A2873	Anti-ICAM3 / CD50	Anti-ICAM3 / CD50 is an IgG1 monoclonal antibody against intercellular adhesion molecules-3 (ICAM-3, also known as CD50)) with the potential to have anti-proliferative activities. MW: 145.22 KD.
E1558New	GSK-3008348 HCl	GSK-3008348 HCl is a small molecule antagonist of integrin αvβ6 with an affinity (pIC50) value of 8.1 for αvβ6 in cell Adhesion assays.
S0314	TR-14035	TR-14035 (SB 683698, MDK-1191) is a a dual alpha4beta (α4β) integrin antagonist with IC50 of 7 nM and 87 nM for alpha4beta7 (α4β7) and alpha4beta1 (α4β1), respectively.
E4615New	GLPG0187	GLPG0187 is a broad-spectrum antagonist of integrin receptor. It inhibits αvβ1-integrin with an IC50 value of 1.3 nM. GLPG0187 also inhibits migrasome biogenesis without cytotoxicity. GLPG0187 exhibits potent antitumor activity.
A2464	Bersanlimab (Anti-ICAM1 / CD54)	Bersanlimab (Anti-ICAM1 / CD54) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects. MW: 145.5 KD.
S4513	RGD peptide (GRGDNP)	RGD peptide (GRGDNP) is an inhibitor of binding of integrins to the extracellular matrixs. RGD peptide (GRGDNP) induces apoptosis presumably through direct activation of caspase-3.	Tradit Med Res, 2023, 8(9):50
E0790	ILK-IN-3	ILK-IN-3 is an integrin linked kinase (ILK) inhibitor with antitumor activity.
A2704	Anti-Integrin aVb6 (ITGAV & ITGB6) (STX-100)	Anti-Integrin aVb6 (ITGAV & ITGB6) (STX-100) is a humanized monoclonal antibody directed against the alpha v beta 6 (αvβ6) integrin. It has a potential to be used in research on Idiopathic Pulmonary Fibrosis (IPF). MW : 144.88 kD.
A2712	Erlizumab (Anti-Integrin b2 / ITGB2 / CD18)	Erlizumab (anti-Integrin b2 / ITGB2 / CD18) is a humanized monoclonal antibody targeted against Integrin beta-2 and used as a therapy for hemorrhagic shock. MW: 146.66 kD.
A2988	Vatelizumab (Anti-Integrin a2b1 (ITGA2 & ITGB1))	Vatelizumab (Anti-Integrin a2b1 (ITGA2 & ITGB1)) is a monoclonal antibody targeting the α2 subunit (CD49b) of very late antigen-2 (VLA-2). It can be used for the research of multiple sclerosis. MW: 144.56 KD.
A2990	Intetumumab (Anti-Integrin aV / ITGAV / CD51)	Intetumumab (Anti-Integrin aV / ITGAV / CD51) is a potent monoclonal antibody targeting αV-integrins. It can be used in research of uterine serous papillary carcinoma (USPC) treatment. MW :145.58 KD.
A2991	Etaracizumab (Anti-Integrin aVb3 (ITGAV & ITGB3))	Etaracizumab (Anti-Integrin aVb3 (ITGAV & ITGB3)) is an IgG1 monoclonal antibody targeting αvβ3 integrin. It inhibits angiogenesis and melanoma tumor growth and can be used to research anticancer. MW :144.18 KD.
A2744	Abituzumab (Anti-Integrin aV / ITGAV / CD51)	Abituzumab (Anti-Integrin aV / ITGAV / CD51) is a humanized monoclonal antibody directed against the human alpha v integrin subunit with potential antiangiogenic and antineoplastic activities.MW: 144.78 kD.
A2745	Anti-Integrin a11 / ITAG11	Anti-Integrin a11 / ITAG11 is a monoclonal antibody against Integrin alpha 11 (ITGA11), a transmembrane glycoprotein expressed in adult cardiac and uterine smooth muscle and developing myocytes. MW: 145.7 KD.
A2761	Abrilumab (Anti-Integrin a4b7 ITGA4 & ITGB7)	Abrilumab (Anti-Integrin a4b7 ITGA4 & ITGB7) is a fully human monoclonal immunoglobulin G2 antibody that targets the alpha4beta7 integrin and prevents interaction with MADCAM-1. It has the potential to be used in research on inflammatory bowel disease (IBD). MW: 143.8 kD.
E1385New	Bexotegrast	Bexotegrast(PLN-74809) is potent dual selective inhibitor of αvβ6 and αvβ1 integrins with Kd of 5.7 nM and 3.4 nM, respectively. It has antifibrogenic effects, blocks multiple TGF-β activation pathways in the fibrotic lung, and is useful for researching fibrosis, including idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
S3408	A286982	A-286982 is a potent, nonpeptide inhibitor of LFA-1/ICAM-1 interaction with IC50s of 44 nM and 35 nM in an LFA-1/ICAM-1 binding assay and LFA-1-mediated cellular adhesion assay, respectively.
A2045	Vedolizumab (anti-α4β7-integrin)	Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
S8306	Leukadherin-1	Leukadherin-1 (LA1) is a small molecule agonist that enhances CD11b/CD18-dependent cell adhesion to its ligand ICAM-1(an agonist for the complement receptor 3 (CD11b/CD18)).	International Immunopharmacology, 2023, Volume 118 Int Immunopharmacol, 2023, 118:110024 Front Immunol, 2022, 13:919444
E0462	Pyrintegrin	Pyrintegrin is an β1-integrin agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival, also enhances cell-extracellular matrix (ECM) adhesion-mediated integrin signaling.	Signal Transduct Target Ther, 2024, 9(1):109 Signal Transduct Target Ther, 2024, 9(1):109
S7077	Cilengitide trifluoroacetate	Cilengitide (EMD 121974, NSC 707544) is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.	Adv Sci (Weinh), 2023, e2307206. Heliyon, 2023, 9(9):e20185 Heliyon, 2023, 9(9):e20185
S6387	Cilengitide	Cilengitide (EMD 121974, EMD-12192, EMD-85189, NSC-​707544) is a potent and selective inhibitor of the integrins ανβ3 and ανβ5 with IC50 of 4 and 79 nM, respectively.	NPJ Regen Med, 2024, 9(1):4 World J Gastroenterol, 2024, 30(7):728-741 Cancer Cell, 2023, 41(8):1480-1497.e9
S7540	SB273005	SB273005 is a potent integrin inhibitor with Ki of 1.2 nM and 0.3 nM for αvβ3 receptor and αvβ5 receptor, respectively.	Cancer Lett, 2024, 582:216597 Nat Commun, 2023, 14(1):3251 Neuron, 2023, S0896-6273(23)00623-2
S8008	RGD (Arg-Gly-Asp) Peptides	RGD (Arg-Gly-Asp) Peptides is a cell adhesion motif which can mimic cell adhesion proteins and bind to integrins.	J Sport Health Sci, 2024, S2095-2546(24)00124-8 iScience, 2024, 27(3):109119 Cell Stem Cell, 2023, 30(6):867-884.e11
S7844	Cyclo(RGDyK)	Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with IC50 of 20 nM.	J Clin Invest, 2024, e175147 Cell Commun Signal, 2023, 10.1186/s12964-022-01027-7 iScience, 2023, 26(6):106839
S7834	Cyclo(-RGDfK) TFA	Cyclo(-RGDfK) TFA is a potent and selective αvβ3 integrin inhibitor.	Sci Adv, 2024, 10(43):eadp4726 bioRxiv, 2024, 2024.09.17.613509 Oxidative Medicine and Cellular Longevity, 2021, 10.1155/2021/9739977
S2885	A-205804	A-205804 is a potent and selective inhibitor of E-selectin and ICAM-1 expression with IC50 of 20 nM and 25 nM respectively.	Cell Biol Toxicol, 2024, 40(1):90 Stem Cell Res Ther, 2022, 13(1):218 Am J Rhinol Allergy, 2022, 19458924221086061
S6840	OSU-T315	OSU-T315 (ILK-IN-2) is a potent Integrin-Linked Kinase (ILK) inhibitor with IC50 of 0.6 μM. OSU-T315 induces autophagy and apoptosis, both of which are integral to its antiproliferative activity. OSU-T315 exhibits anti-tumor activity.	Exp Eye Res, 2023, 234:109609
S4513	RGD peptide (GRGDNP)	RGD peptide (GRGDNP) is an inhibitor of binding of integrins to the extracellular matrixs. RGD peptide (GRGDNP) induces apoptosis presumably through direct activation of caspase-3.	Tradit Med Res, 2023, 8(9):50
E0790	ILK-IN-3	ILK-IN-3 is an integrin linked kinase (ILK) inhibitor with antitumor activity.
E1385New	Bexotegrast	Bexotegrast(PLN-74809) is potent dual selective inhibitor of αvβ6 and αvβ1 integrins with Kd of 5.7 nM and 3.4 nM, respectively. It has antifibrogenic effects, blocks multiple TGF-β activation pathways in the fibrotic lung, and is useful for researching fibrosis, including idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
S3408	A286982	A-286982 is a potent, nonpeptide inhibitor of LFA-1/ICAM-1 interaction with IC50s of 44 nM and 35 nM in an LFA-1/ICAM-1 binding assay and LFA-1-mediated cellular adhesion assay, respectively.
A2420	Anti-Integrin b1 / ITGB1 / CD29	Anti-Integrin b1 / ITGB1 / CD29 is a humanized monoclonal antibody directed against the human integrin receptor beta-1 subunit (CD29), with potential antineoplastic activity. MW: 145.5 kD.
A2873	Anti-ICAM3 / CD50	Anti-ICAM3 / CD50 is an IgG1 monoclonal antibody against intercellular adhesion molecules-3 (ICAM-3, also known as CD50)) with the potential to have anti-proliferative activities. MW: 145.22 KD.
A2464	Bersanlimab (Anti-ICAM1 / CD54)	Bersanlimab (Anti-ICAM1 / CD54) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects. MW: 145.5 KD.
A2704	Anti-Integrin aVb6 (ITGAV & ITGB6) (STX-100)	Anti-Integrin aVb6 (ITGAV & ITGB6) (STX-100) is a humanized monoclonal antibody directed against the alpha v beta 6 (αvβ6) integrin. It has a potential to be used in research on Idiopathic Pulmonary Fibrosis (IPF). MW : 144.88 kD.
A2712	Erlizumab (Anti-Integrin b2 / ITGB2 / CD18)	Erlizumab (anti-Integrin b2 / ITGB2 / CD18) is a humanized monoclonal antibody targeted against Integrin beta-2 and used as a therapy for hemorrhagic shock. MW: 146.66 kD.
A2988	Vatelizumab (Anti-Integrin a2b1 (ITGA2 & ITGB1))	Vatelizumab (Anti-Integrin a2b1 (ITGA2 & ITGB1)) is a monoclonal antibody targeting the α2 subunit (CD49b) of very late antigen-2 (VLA-2). It can be used for the research of multiple sclerosis. MW: 144.56 KD.
A2990	Intetumumab (Anti-Integrin aV / ITGAV / CD51)	Intetumumab (Anti-Integrin aV / ITGAV / CD51) is a potent monoclonal antibody targeting αV-integrins. It can be used in research of uterine serous papillary carcinoma (USPC) treatment. MW :145.58 KD.
A2991	Etaracizumab (Anti-Integrin aVb3 (ITGAV & ITGB3))	Etaracizumab (Anti-Integrin aVb3 (ITGAV & ITGB3)) is an IgG1 monoclonal antibody targeting αvβ3 integrin. It inhibits angiogenesis and melanoma tumor growth and can be used to research anticancer. MW :144.18 KD.
A2744	Abituzumab (Anti-Integrin aV / ITGAV / CD51)	Abituzumab (Anti-Integrin aV / ITGAV / CD51) is a humanized monoclonal antibody directed against the human alpha v integrin subunit with potential antiangiogenic and antineoplastic activities.MW: 144.78 kD.
A2745	Anti-Integrin a11 / ITAG11	Anti-Integrin a11 / ITAG11 is a monoclonal antibody against Integrin alpha 11 (ITGA11), a transmembrane glycoprotein expressed in adult cardiac and uterine smooth muscle and developing myocytes. MW: 145.7 KD.
A2761	Abrilumab (Anti-Integrin a4b7 ITGA4 & ITGB7)	Abrilumab (Anti-Integrin a4b7 ITGA4 & ITGB7) is a fully human monoclonal immunoglobulin G2 antibody that targets the alpha4beta7 integrin and prevents interaction with MADCAM-1. It has the potential to be used in research on inflammatory bowel disease (IBD). MW: 143.8 kD.
A2045	Vedolizumab (anti-α4β7-integrin)	Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
S8454	ATN-161	ATN-161 is a novel small peptide antagonist of integrin α5β1. It binds to several integrins, including α5β1 and αvβ3, that play a role in angiogenesis and tumor progression.	Nat Commun, 2024, 15(1):5986 Int Immunopharmacol, 2024, 141:112947 Bioact Mater, 2023, 22:75-90
S3714	Lifitegrast	Lifitegrast (SAR1118,SHP-606) is a novel small molecule integrin antagonist that inhibits a specific T cell-mediated inflammatory pathway involved in the pathogenesis of DED.	Med Oncol, 2024, 41(8):188 World J Gastroenterol, 2023, 29(20):3103-3118 Med Chem Res, 2022, 31(4):555-579
S3085	Tirofiban	Tirofiban (MK-383) is a selective platelet GPIIb/IIIa antagonist which inhibits platelet aggregation with IC50 of 9 nM.	Food Funct, 2020, 11(1):139-152
S8594	Tirofiban Hydrochloride	Tirofiban Hydrochloride (MK-383) is the hydrochloride salt form of tirofiban, a selective platelet GPIIb/IIIa antagonist which inhibits platelet aggregation. It is more soluable than Tirofiban.	J Immunother Cancer, 2024, 12(11)e009805 Transl Oncol, 2024, 39:101813 Front Cell Infect Microbiol, 2021, 11:783085
E1558New	GSK-3008348 HCl	GSK-3008348 HCl is a small molecule antagonist of integrin αvβ6 with an affinity (pIC50) value of 8.1 for αvβ6 in cell Adhesion assays.
S0314	TR-14035	TR-14035 (SB 683698, MDK-1191) is a a dual alpha4beta (α4β) integrin antagonist with IC50 of 7 nM and 87 nM for alpha4beta7 (α4β7) and alpha4beta1 (α4β1), respectively.
E4615New	GLPG0187	GLPG0187 is a broad-spectrum antagonist of integrin receptor. It inhibits αvβ1-integrin with an IC50 value of 1.3 nM. GLPG0187 also inhibits migrasome biogenesis without cytotoxicity. GLPG0187 exhibits potent antitumor activity.
S8306	Leukadherin-1	Leukadherin-1 (LA1) is a small molecule agonist that enhances CD11b/CD18-dependent cell adhesion to its ligand ICAM-1(an agonist for the complement receptor 3 (CD11b/CD18)).	International Immunopharmacology, 2023, Volume 118 Int Immunopharmacol, 2023, 118:110024 Front Immunol, 2022, 13:919444
E0462	Pyrintegrin	Pyrintegrin is an β1-integrin agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival, also enhances cell-extracellular matrix (ECM) adhesion-mediated integrin signaling.	Signal Transduct Target Ther, 2024, 9(1):109 Signal Transduct Target Ther, 2024, 9(1):109
E1558New	GSK-3008348 HCl	GSK-3008348 HCl is a small molecule antagonist of integrin αvβ6 with an affinity (pIC50) value of 8.1 for αvβ6 in cell Adhesion assays.
E4615New	GLPG0187	GLPG0187 is a broad-spectrum antagonist of integrin receptor. It inhibits αvβ1-integrin with an IC50 value of 1.3 nM. GLPG0187 also inhibits migrasome biogenesis without cytotoxicity. GLPG0187 exhibits potent antitumor activity.
E1385New	Bexotegrast	Bexotegrast(PLN-74809) is potent dual selective inhibitor of αvβ6 and αvβ1 integrins with Kd of 5.7 nM and 3.4 nM, respectively. It has antifibrogenic effects, blocks multiple TGF-β activation pathways in the fibrotic lung, and is useful for researching fibrosis, including idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).